Lower cytokine secretion, potentially reducing the risk of dangerous side effects such as CRS and ICANs, two of the most severe side effects limiting CAR-T and traditional CD3-TCE adoption in ...

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, ...

New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ ... Because our γδ T cells express CD16 and CD3, they can potentially be combined with monoclonal antibodies or bispecifics ...

CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers, forms the TCR-CD3 complex. This complex is crucial for coupling antigen ...

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency; INB-619, a next generation γδ ...

INB-600 is a novel gamma-delta T cell engager targeting CD19 ... the durability of response and safety compared to existing CD3 targeting TCE therapies. Throughout 2025, we remain focused on ...

GammaDelta’s drug platform is based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role to many types of immune responses and immunopathology.

Reports as of December 31 the company had cash of $11.1M as of December 31, compared with $21.3M as of December 31, 2023. Subsequently, in ...

Compared with healthy and erythrodermic control individuals, the patient’s CD3+ IL-4– and IL-13–secreting cells showed an elevated population of clonal gamma V delta 2 T cells (3.13%).

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) ...